Seher et al. treated MM cell lines in vitro with custom-designed BMP-2 variants and confirmed that there was an antagonistic effect on Activin A, as well as a BMP-2 agonistic effect, which could lead to overall net bone gain, as well as potential antitumour effects [95]. The gene discussed is BMP2; the disease is Miyoshi myopathy.